SLC35A2 and breast carcinoma: Another example of UGT somatic mutations that may have an impact on drug responses relates to the treatment of estrogen receptor-positive breast cancers with antiestrogens such as tamoxifen (TAM) and aromatase inhibitors such as exemestane (EXE) [111].